Business
AIM ImmunoTech develops Ampligen, also known as rintatolimod, and Alferon N Injection for cancers, viral diseases, and immune-system disorders.
AIM ImmunoTech cut cash burn and narrowed its net loss, but revenue fell to $88K and equity stayed negative.
The read at a glance✓ Audited against SEC data
- Business mix — Ampligen-focused biotechNote
- Revenue — Revenue fell 48.2% to $88KWatch
- Profitability — Net loss was $14.0MWatch
- Cash — Free cash flow was -$11.0MWatch
- Balance sheet — Equity deficit widened to $9.8MWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; EQ unavailableWatch
Latest filings
- DEF 14A · Annual proxy (pay & governance)2026-09-30
- 8-K · Company announcement2026-09-14
- 8-K · Company announcement2026-09-10
- 8-K · Company announcement2026-09-04
- 8-K · Company announcement2026-08-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AIM ImmunoTech Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.